A Study of BGB-11417 in Participants With Myeloid Malignancies

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

February 8, 2028

Study Completion Date

February 8, 2028

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
Interventions
DRUG

BGB-11417

Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.

DRUG

Azacitidine

Intravenous or subcutaneous administration for 7 days.

DRUG

Posaconazole

Oral administration for 8 days on second cycle only.

DRUG

BGB-11417

Oral administration for 28 days on a 28-day cycle.

DRUG

BGB-11417

Oral administration for 10, 14 or 21 days on a 28-day

Trial Locations (49)

2025

ACTIVE_NOT_RECRUITING

Aotearoa Clinical Trials, Auckland

6021

RECRUITING

Wellington Regional Hospital (Ccdhb), Wellington

20162

RECRUITING

Niguarda Cancer Center Division of Hematology, Milan

37007

RECRUITING

Hospital Universitario de Salamanca, Salamanca

40138

RECRUITING

Policlinico Sorsola Malpighi, Aou Di Bologna, Bologna

41013

RECRUITING

Hospital Universitario Virgen Del Rocio, Seville

46026

RECRUITING

Hospital Universitari I Politecnic La Fe, Valencia

47014

RECRUITING

Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst, Meldola

59000

RECRUITING

Hopital Claude Huriez Chu Lille, Lille

75010

RECRUITING

Hopital Saint Louis, Paris

89081

RECRUITING

Universitaetsklinikum Ulm, Ulm

100044

RECRUITING

Peking University Peoples Hospital, Beijing

215006

RECRUITING

The First Affiliated Hospital of Soochow University, Suzhou

300060

COMPLETED

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310003

RECRUITING

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

330006

RECRUITING

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

430022

RECRUITING

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

450000

RECRUITING

Henan Cancer Hospital, Zhengzhou

510080

RECRUITING

Guangdong Provincial Peoples Hospital, Guangzhou

510515

RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

518037

COMPLETED

The Second Peoples Hospital of Shenzhen, Shenzhen

610041

RECRUITING

West China Hospital, Sichuan University, Chengdu

730000

RECRUITING

The First Hospital of Lanzhou University, Lanzhou

91010-3012

COMPLETED

City of Hope National Medical Center, Duarte

33606-3571

RECRUITING

Tampa General Hospital, Tampa

15232-1309

RECRUITING

Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh

77030-3907

RECRUITING

Md Anderson Cancer Center, Houston

53226-1222

RECRUITING

Medical College of Wisconsin, Milwaukee

NSW 2139

RECRUITING

Concord Repatriation General Hospital, Concord

NSW 2217

RECRUITING

St George Hospital, Kogarah

NSW 2800

RECRUITING

Orange Health Hospital, Orange

QLD 4215

RECRUITING

Gold Coast University Hospital, Southport

VIC 3168

RECRUITING

Monash Health, Clayton

VIC 3065

RECRUITING

St Vincents Hospital Melbourne, Fitzroy

VIC 3084

RECRUITING

Austin Health, Heidelberg

VIC 3004

RECRUITING

The Alfred Hospital, Melbourne

WA 6150

RECRUITING

Fiona Stanley Hospital, Murdoch

WA 6009

RECRUITING

Linear Clinical Research, Nedlands

RECRUITING

One Clinical Research, Nedlands

06200

RECRUITING

Hopital Larchet, Nice

04103

RECRUITING

Universitaetsklinikum Leipzig Aor, Leipzig

0622

RECRUITING

North Shore Hospital, Auckland

06351

RECRUITING

Samsung Medical Center, GangnamGu

03722

RECRUITING

Severance Hospital Yonsei University Health System, SeodaemunGu

03080

RECRUITING

Seoul National University Hospital, Seoul

05505

RECRUITING

Asan Medical Center, SongpaGu

08041

RECRUITING

Hospital de La Santa Creu I Sant Pau, Barcelona

EH4 2XU

RECRUITING

Edinburgh Cancer Centre, Edinburgh

M20 4BX

RECRUITING

The Christie Hospital, Greater Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY